Table of Contents
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
Chapter 6. Global Type-1 Diabetes Treatment Market, by Product
6.1 Introduction
6.2 Rapid-Acting Insulin
6.2.1 Admelog
6.2.2 Humalog
6.2.3 Novolog
6.2.3 Others
6.3 Short-Acting insulin
6.4 Intermediate-Acting insulin
6.5 Long-Acting insulin
6.5.1 Lantus
6.5.2 Levemir
6.5.2 Others
6.5 Others
Chapter 7. Global Type-1 Diabetes Treatment Market, by End User
7.1 Introduction
7.2 Hospitals & Clinics
7.3 Specialty Centers
7.4 Others
Chapter 8. Global Type-1 Diabetes Treatment Market, by Region
8.1 Introduction
8.2 Americas
8.2.1 North America
8.2.1.1 US
8.2.1.2 Canada
8.2.2 Latin America
8.3 Europe
8.3.1 Western Europe
8.3.1.1 Germany
8.3.1.2 France
8.3.1.3 Italy
8.3.1.4 Spain
8.3.1.5 UK
8.3.1.6 Rest of Western Europe
8.3.2 Eastern Europe
8.4 Asia-Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia-Pacific
8.5 Middle East & Africa
8.5.1 UAE
8.5.2 Saudi Arabia
8.5.3 Oman
8.5.4 Kuwait
8.5.5 Qatar
8.5.6 Rest of the Middle East & Africa
Chapter 9. Competitive Landscape
9.1 Introduction
9.2 Market Share Analysis
9.3 Key Developments & Strategies
9.3.1 Key Developments
Chapter 10 Company Profiles
10.1 Astellas Pharma
10.1.1. Company Overview
10.1.2. Financial Overview
10.1.3. Products Offered
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2 Eli Lilly
10.2.1 Company Overview
10.2.2 Financial Overview
10.2.3 Products Offered
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.2.6 Key Strategies
10.3 Merck
10.3.1 Company Overview
10.3.2 Financial Overview
10.3.3 Products Offered
10.3.4 Key Developments
10.3.5 SWOT Analysis
10.3.6 Key Strategies
10.4 Novo Nordisk
10.4.1 Company Overview
10.4.2 Financial Overview
10.4.3 Products Offered
10.4.4 Key Developments
10.4.5 SWOT Analysis
10.4.6 Key Strategies
10.5 Sanofi
10.5.1 Company Overview
10.5.2 Financial Overview
10.5.3 Products Offered
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.5.6 Key Strategies
10.6 AstraZeneca
10.6.1 Company Overview
10.6.2 Financial Overview
10.6.3 Products Offered
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.6.6 Key Strategies
10.7 Boehringer Ingelheim GmbH
10.7.1 Company Overview
10.7.2 Financial Overview
10.7.3 Products Offered
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.7.6 Key Strategies
10.8 Novartis
10.8.1 Company Overview
10.8.2 Financial Overview
10.8.3 Products Offered
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.8.6 Key Strategies
10.9 Pfizer Inc.
10.9.1 Company Overview
10.9.2 Financial Overview
10.9.3 Products Offered
10.9.4 Key Developments
10.9.5 SWOT Analysis
10.9.6 Key Strategies
10.10 Abbott Laboratories
10.10.1 Company Overview
10.10.2 Financial Overview
10.10.3 Products Offered
10.10.4 Key Developments
10.10.5 SWOT Analysis
10.10.6 Key Strategies
10.11 Mannkind Corporation
10.11.1 Company Overview
10.11.2 Financial Overview
10.11.3 Products Offered
10.11.4 Key Developments
10.11.5 SWOT Analysis
10.11.6 Key Strategies
10.12 B. Braun Melsungen AG
10.12.1 Company Overview
10.12.2 Financial Overview
10.12.3 Products Offered
10.12.4 Key Developments
10.12.5 SWOT Analysis
10.12.6 Key Strategies
10.13 Macrogenics, Inc.
10.13.1 Company Overview
10.13.2 Financial Overview
10.13.3 Products Offered
10.13.4 Key Developments
10.13.5 SWOT Analysis
10.13.6 Key Strategies
10.14 DiaVacs, Inc.
10.14.1 Company Overview
10.14.2 Financial Overview
10.14.3 Products Offered
10.14.4 Key Developments
10.14.5 SWOT Analysis
10.14.6 Key Strategies
10.15 Biodel, Inc.
10.15.1 Company Overview
10.15.2 Financial Overview
10.15.3 Products Offered
10.15.4 Key Developments
10.15.5 SWOT Analysis
10.15.6 Key Strategies
Chapter 11. Appendix
11.1. References
11.2. Related Reports
LIST OF TABLES
Table 1 Global Type-1 Diabetes Treatment Synopsis, 2020-2027
Table 2 Global Type-1 Diabetes Treatment Market Estimates & Forecast, 2020-2027 (USD Million)
Table 3 Global Type-1 Diabetes Treatment Market, by Region 2020-2027 (USD Million)
Table 4 Global Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)
Table 5 Global Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)
Table 6 Americas: Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)
Table 7 Americas: Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)
Table 8 Americas: Type-1 Diabetes Treatment Market, by Region 2020-2027 (USD Million)
Table 9 North America: Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)
Table 10 North America: Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)
Table 11 Latin America: Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)
Table 12 Latin America: Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)
Table 13 Europe: Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)
Table 14 Europe: Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)
Table 15 Europe: Type-1 Diabetes Treatment Market, by Region 2020-2027 (USD Million)
Table 16 Western Europe: Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)
Table 17 Western Europe: Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)
Table 18 Eastern Europe: Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)
Table 19 Eastern Europe: Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)
Table 20 Asia-Pacific: Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)
Table 21 Asia-Pacific: Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)
Table 22 Middle East & Africa: Type-1 Diabetes Treatment Market, by Product 2020-2027 (USD Million)
Table 23 Middle East & Africa: Type-1 Diabetes Treatment Market, by End User 2020-2027 (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation of the Global Type-1 Diabetes Treatment Market
Figure 3 Market Dynamics for the Global Type-1 Diabetes Treatment Market
Figure 4 Global Type-1 Diabetes Treatment Market Share, by Product, 2020
Figure 5 Global Type-1 Diabetes Treatment Market Share, by End User, 2020
Figure 6 Global Type-1 Diabetes Treatment Market Share, by Region, 2020
Figure 7 Americas: Type-1 Diabetes Treatment Market Share, by Region, 2020
Figure 8 North America: Type-1 Diabetes Treatment Market Share, by Country, 2020
Figure 9 Latin America: Type-1 Diabetes Treatment Market Share, by Country, 2020
Figure 10 Europe: Type-1 Diabetes Treatment Market Share, by Country, 2020
Figure 11 Asia-Pacific: Type-1 Diabetes Treatment Market Share, by Country, 2020
Figure 12 Middle East & Africa: Type-1 Diabetes Treatment Market Share, by Country, 2020
Figure 13 Global Type-1 Diabetes Treatment Market: Company Share Analysis, 2020 (%)
Figure 14 Astellas Pharma: Key Financials
Figure 15 Astellas Pharma: Segmental Revenue
Figure 16 Astellas Pharma: Regional Revenue
Figure 17 Eli Lilly: Key Financials
Figure 18 Eli Lilly: Segmental Revenue
Figure 19 Eli Lilly: Regional Revenue
Figure 20 Merck: Key Financials
Figure 21 Merck: Segmental Revenue
Figure 22 Merck: Regional Revenue
Figure 23 Sanofi: Key Financials
Figure 24 Sanofi: Segmental Revenue
Figure 25 Sanofi: Regional Revenue
Figure 26 Novo Nordisk: Key Financials
Figure 27 Novo Nordisk: Segmental Revenue
Figure 28 Novo Nordisk: Regional Revenue
Figure 29 Biodel, Inc.: Key Financials
Figure 30 Biodel, Inc.: Segmental Revenue
Figure 31 Biodel, Inc.: Regional Revenue
Figure 32 DiaVacs, Inc.: Key Financials
Figure 33 DiaVacs, Inc.: Segmental Revenue
Figure 34 DiaVacs, Inc.: Regional Revenue
Figure 35 Macrogenics, Inc.: Key Financials
Figure 36 Macrogenics, Inc.: Segmental Revenue
Figure 37 Macrogenics, Inc.: Regional Revenue
Figure 38 B. Braun Melsungen AG: Key Financials
Figure 39 B. Braun Melsungen AG: Segmental Revenue
Figure 40 B. Braun Melsungen AG: Regional Revenue
Figure 41 Mannkind Corporation: Key Financials
Figure 42 Mannkind Corporation: Segmental Revenue
Figure 43 Mannkind Corporation: Regional Revenue
Figure 44 Pfizer Inc.: Key Financials
Figure 45 Pfizer Inc.: Segmental Revenue
Figure 46 Pfizer Inc.: Regional Revenue
Figure 47 Abbott Laboratories: Key Financials
Figure 48 Abbott Laboratories: Segmental Revenue
Figure 49 Abbott Laboratories: Regional Revenue
Figure 50 Novartis: Key Financials
Figure 51 Novartis: Segmental Revenue
Figure 52 Novartis: Regional Revenue
Figure 53 Boehringer Ingelheim GmbH: Key Financials
Figure 54 Boehringer Ingelheim GmbH: Segmental Revenue
Figure 55 Boehringer Ingelheim GmbH: Regional Revenue
Figure 56 AstraZeneca: Key Financials
Figure 57 AstraZeneca: Segmental Revenue
Figure 58 AstraZeneca: Regional Revenue
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
